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Abstract: Vaccine development relies on testing vaccine candidates in animal models. However,
results from animals cannot always be translated to humans. Alternative ways to screen vaccine
candidates before clinical trials are therefore desirable. Dendritic cells (DCs) are the main orchestrators
of the immune system and the link between innate and adaptive responses. Their activation by
vaccines is an essential step in vaccine-induced immune responses. We have systematically evaluated
the suitability of two different human DC-based systems, namely the DC-cell line MUTZ-3 and
primary monocyte-derived DCs (Mo-DCs) to screen immunopotentiating properties of vaccine
candidates. Two different influenza vaccine formulations, whole inactivated virus (WIV) and subunit
(SU), were used as model antigens as they represent a high immunogenic and low immunogenic
vaccine, respectively. MUTZ-3 cells were restricted in their ability to respond to different stimuli.
In contrast, Mo-DCs readily responded to WIV and SU in a vaccine-specific way. WIV stimulation
elicited a more vigorous induction of activation markers, immune response-related genes and
secretion of cytokines involved in antiviral responses than the SU vaccine. Furthermore, Mo-DCs
differentiated from freshly isolated and freeze/thawed peripheral blood mononuclear cells (PBMCs)
showed a similar capacity to respond to different vaccines. Taken together, we identified human
PBMC-derived Mo-DCs as a suitable platform to evaluate vaccine-induced immune responses.
Importantly, we show that fresh and frozen PBMCs can be used indistinctly, which strongly facilitates
the routine use of this system. In vitro vaccine pre-screening using human Mo-DCs is thus a promising
approach for evaluating the immunopotentiating capacities of new vaccine formulations that have
not yet been tested in humans.
Keywords: dendritic cell; MUTZ-3; whole inactivated virus influenza vaccine; subunit influenza
vaccine; flow cytometry; qPCR; cytokines
1. Introduction
Vaccines are the most cost-effective way to battle infectious diseases. Their routine use has
enabled the eradication of infectious diseases like smallpox and rinderpest, and the reduction of
others like measles and pertussis [1]. However, the development of new vaccines is both expensive
and time-consuming, with rarely successful outcomes. Currently, the use of animal models is a key
step in assessing vaccine safety and efficacy. However, the use of animals in preclinical studies has
disadvantages. Apart from the intrinsic ethical issues that come with their use, animal models cannot
completely mimic the immune system of humans [2]. Frequently, vaccine candidates that succeeded
in animal experiments fail to do so in clinical trials, this being one of the greatest bottlenecks when
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screening vaccines [3,4]. Given the limitations of the current animal models, the use of alternative
tools to predict vaccine behavior in humans could increase the odds of success of vaccine candidates
in clinical trials.
Cultures of antigen-presenting cells (APCs) could provide insights into how the human immune
system responds to a vaccine batch or a new vaccine candidate. In the past, human primary cells
differentiated to APCs or cell lines representing APCs have allowed us to model and to gain insight
into basic immunological responses, e.g., the differentiation of monocytes into APCs, the induction of
antigen-specific T helper and memory cells, and the induction of antigen-specific antibody responses
(reviewed in [5,6]). An important type of APCs is the dendritic cell (DC), which acts as sentinel of the
immune system by detecting the presence of pathogens or vaccines. The key functional features of
DCs are to capture, process and present antigens and to deliver accessory signals thereby enabling
T cell priming [7]. DCs have a pivotal role in the induction of immune responses, their effects on other
immune cells (both innate and adaptive) have great consequences for the adaptive immune response
after vaccination [8].
There are two possible sources of human DCs for the investigation of vaccines in vitro: DC-like cell
lines and primary DCs isolated and differentiated from peripheral blood mononuclear cells (PBMCs).
Generally, the use of cell lines to evaluate immune responses is very appealing since cell lines are
a consistent source of stable cells, they are readily available, and they are not subject to variation.
However, cell lines have accumulated mutations, amongst others mutations enabling their continuous
growth, and thus may no longer respond to triggers in the same way as normal cells would [9]. Primary
DCs, on the other hand, require a laborious process of isolation of monocytes from PBMCs and their
subsequent differentiation to DC; the sources for PBMCs are limited and more importantly, responses
of PBMC-derived DCs might be prone to donor-to-donor variation [10,11]. Notwithstanding, primary
cells retain many of the characteristics of the cells in vivo which may translate into a more accurate
response than the that obtained with cell lines.
As a first step towards the development of an in vitro system suitable for pre-screening of vaccine
candidates, we set out to identify the best cellular platform to assess in vitro stimulatory properties of
vaccine formulations. We have evaluated the responses upon stimulation with vaccines in a DC-like
cell line, and in human monocyte-derived DCs (Mo-DCs). As a representative of DC-like cell lines
we chose MUTZ-3, a human acute myeloid leukemia cell line. The differentiation of this myeloid cell
line to a DC phenotype is dependent on cytokines [12,13] rather than on lipopolysaccharide (LPS)
stimulation or pharmacological agents as required for other cell lines. Thus, the conditions MUTZ-3
cells need for differentiation resemble the conditions used to obtain monocyte-derived DCs from
primary cells, which confers MUTZ-3 an advantage over other APC-like cell lines [14]. With respect to
Mo-DCs, we determined whether freshly isolated and frozen/thawed PBMCs are equally suitable for
generation of Mo-DCs and whether Mo-DCs derived from fresh and frozen PBMCs respond to vaccines
and do so in a similar way. The use of frozen/thawed PBMCs has so far not been systematically
evaluated. Frozen PBMCs as source of monocytes for DC differentiation would make the use of a
human primary DC-based platform much more practical, reproducible and efficient. In addition, we
evaluated the extent of donor-to-donor variation in the response to vaccines which has so far gained
limited attention.
As model antigens we used two different non-adjuvanted influenza vaccine formulations
with well-characterized differences in immunogenicity: whole inactivated virus (WIV) and subunit
(SU) vaccine. WIV vaccines, produced by inactivation of live virus with formaldehyde or
β-propiolactone [15], retain the native virus structure, contain all viral proteins, and possess fusion
activity. They also contain single-stranded RNA (ssRNA), which triggers toll-like receptor (TLR) 7
and thus provides a “self-adjuvanted” feature to WIV [16,17]. These characteristics make WIV more
immunogenic than SU. The SU vaccine is a highly purified formulation consisting of the viral surface
antigens hemagglutinin (HA) and neuraminidase (NA). This vaccine is produced by purification of
HA and NA from an inactivated detergent-disrupted influenza virus [18]. Intrinsic differences in the
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immune responses elicited by the two vaccine formulations have been reported previously in animal
models as well as in unprimed humans [19]. Compared to SU vaccines, WIV vaccines have shown to
induce higher immonuglobulin G2a (IgG2a) levels against HA and NA [16], higher hemagglutination
inhibition titers, a Th1-type (rather than a Th2-type) response [20] and cross-protective cytotoxic T cells
in immunized mice [21]. The in vivo results were reflected by in vitro results, demonstrating that
WIV induces in mouse DCs a Th1 cytokine profile and prominent changes in the expression of genes
involved in antiviral pathways, whereas SU did not [22].
Here we report that human Mo-DCs respond to WIV and SU vaccines in a vaccine-specific
manner whilst the MUTZ-3 cell line does not. We demonstrate that DCs differentiated from freshly
isolated or cryopreserved PBMCs show similar capacities to respond to different vaccines. This enables
the indistinct use of fresh and frozen PBMCs for DC generation, thus facilitating the routine use of
this DC-based in vitro system. DCs derived from different donors responded to the vaccines in a
qualitatively similar way and differed only marginally in quantitative terms for most of our readouts.
The ability of cultured DCs to recapitulate vaccine-specific activation patterns upon stimulation
with different vaccines represents a pivotal requirement for the development of an in vitro screening
platform for the evaluation of novel vaccine formulations.
2. Materials and Methods
2.1. Vaccines
WIV and SU were produced from the H5N1 virus subtype (NIBRG-14, a 2:6 recombinant of
A/Vietnam/1194/2004 (H5N1) and A/PR/8/34 (H1N1) virus produced by reverse genetics technology,
obtained from the NIBSC) as described before [16]. Briefly, H5N1 was propagated on embryonated
chicken eggs and inactivated with 0.1% β-propiolactone for 24 h at 19–21 ◦C, followed by dialysis and
filtration (0.45 µm) to obtain WIV. SU was produced by solubilizing the β-propiolactone-inactivated
virus with the detergent octa(ethyleneglycol)-n-dodecyl monoether (C12E8) (Nikkol, Tokyo, Japan).
Nucleocapsids were removed by ultracentrifugation and membranes were reconstituted by extraction
of C12E8 using Biobeads (Bio-Rad, Hercules, CA, USA). Formed virosomes were concentrated by
ultra-centrifugation on a 50% sucrose cushion in Hepes and then processed into subunit vaccine.
2.2. Generation of DC Derived from the MUTZ-3 Cell Line
The human leukemic cell line MUTZ-3 was obtained from the Leibniz-Institute DSMZ (Deutsche
Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany) and cultured at 37 ◦C
with 5% CO2 in Minimal Essential Medium-α (MEM-α) (Gibco, Life Technologies, Paisley, UK)
supplemented with 20% heat-inactivated fetal calf serum (FCS) (Lonza, Basel, Switzerland), 1%
penicillin/streptomycin and 500 U/mL granulocyte-macrophage colony-stimulating factor (GM-CSF)
(ProsPec, Rehovot, Israel). Cells from passage numbers 10 to 25 were used for differentiation to a DC
phenotype. Differentiation conditions tested are summarized in Appendix (Table A1). The culture
medium was replaced every 3 days. Cells were seeded at a density of 2 × 105 cells/mL in 12-well
plates (Corning; New York, NY, USA) for flow cytometry analysis.
2.3. Generation of Immature Mo-DCs from Primary Cells
PBMCs were isolated from buffy coats (Sanquin, Groningen, The Netherlands). Aliquots
containing 12.5 mL of buffy coat were mixed with 37.5 mL of RPMI-1641 (Gibco, Life Technologies;
Paisley, UK). The mixture was layered on 16 mL of Ficoll Paque (GE Healthcare, Upssala, Sweden)
and the tubes were centrifuged at 400× g for 30 min at 21 ◦C without brake. PBMC fractions were
collected, pooled, resuspended in RPMI and centrifuged at 250× g for 10 min. Red blood cells were
lysed with ACK lysis buffer (156 mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA; pH 7.3) and washed
with RPMI. Cells were centrifuged at 250× g for 10 min, resuspended in 5 mL RPMI + 5% FCS and
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viability was determined by Trypan Blue (Gibco, Rockville, MD, USA). At this stage, cells were either
used directly for isolation of monocytes (see below) or were frozen.
PBMCs were placed in a cell freezing container (CoolCell LX, Biocision, Menlo Park, CA,
USA) and stored in liquid nitrogen at a concentration of 40 × 106 PBMCs/mL per cryotube in FCS
(90%) + dimethyl sulfoxide (DMSO) 10%. Cryotubes containing frozen PBMCs were placed in a water
bath at 37 ◦C until cells were thawed. Cells were pipetted into 15-mL tubes and a 2-fold volume of warm
FCS (37 ◦C) was added slowly. After centrifugation at 500× g for 10 min, cells were washed 2 times
with washing buffer (phosphate-buffered saline (PBS), 2% FCS, 1 mM ethylenediaminetetraacetic acid
(EDTA)), centrifuged and resuspended in washing buffer. Viability was checked with Trypan Blue.
Monocytes from fresh or frozen PBMCs were isolated using an immunomagnetic negative
selection kit, the EasySep Human Monocyte Enrichment Kit (Stemcell Technologies, Vancouver, BC,
Canada). To obtain dendritic cells, monocytes were seeded at a density of 1 × 106 cells/mL and
cultured at 37 ◦C with 5% CO2 in RPMI-1640 medium (L-glutamine, HEPES) supplemented with 10%
FCS, 1% penicillin/streptomycin, GM-CSF (450 U/mL) and interleukin-4 (IL-4) (500 U/mL) (ProsPec,
Rehovot, Israel). Fresh cytokines were added every 2 days for 6 days.
2.4. Treatments
2.4.1. Undifferentiated MUTZ
To check on the MUTZ-3 phenotype before differentiation, cells were stimulated with
lipopolysaccharide (LPS; 1 µg/mL; Invivogen, Toulouse, France), imidazoquinoline compound (R848;
10 µg/mL; Invivogen, Toulouse, France), tumor necrosis factor alpha (TNF-α; 2 µg/mL; PeproTech,
London, UK), whole inactivated influenza virus (WIV; equivalent to 10 µg/mL HA), subunit influenza
vaccine (SU; equivalent to 10 µg/mL HA) or PBS (Gibco, Bleiswijk, The Netherlands) for 24 or 48 h.
2.4.2. MUTZ-3-Derived DCs
After differentiation, stimulation was performed for 24 h with LPS (1 µg/mL), R848 (5 µg/mL),
WIV (equivalent to 10 µg/mL HA), SU (10 µg/mL) or TNF-α (2 µg/mL; PeproTech, Rocky Hill, NJ,
USA). MUTZ-3 cells were seeded at a density of 2 × 105 cells/mL in 12-well plates.
2.4.3. Monocyte-Derived DCs
After differentiation, immature DCs were exposed for 4 or 24 h to WIV or SU vaccines, R848, or
PBS as described above. Cells were seeded at a concentration of 5 × 105 cells/mL per treatment in
12-well plates for qPCR, cytokine and flow cytometry analysis
2.5. Surface Marker Staining and Flow Cytometry Analysis
To examine the expression of surface markers associated with the DC phenotype, 2 × 105 cells of
each condition were harvested after exposure. Cells were fixed in 200 µL of 4% paraformaldehyde
(Merck KGaA, Darmstadt, Germany) in PBS and washed with cold washing buffer (1× PBS
supplemented with 2% FCS and 1 mM EDTA). Cells were stained for 45 min at 4 ◦C in the dark,
washed, and resuspended in 200 µL washing buffer. The following labeled mouse anti-human
antibodies (all from BD Pharmingen, San Diego, CA, USA) were used for flow cytometry analysis:
FITC-MHCII, PE-CD86, APC-CD11c, FITC-CD40, PE-CD80, and APC-CD14. Flow cytometry was
performed on a FACS Calibur flow cytometer (BD Pharmingen, San Diego, CA, USA). Data were
collected using the Cell Quest software (Becton Dickinson) and analyzed using the Kaluza software
(Beckman Coulter, Woerden, The Netherlands) and FlowJo (Tree Star, Inc., Ashland, OR, USA). Isotype
controls were used for all of antibodies used to control for aspecific binding and were negative in
all cases.
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2.6. RNA Isolation and qPCR
Cells from each exposure condition (see results section for details) were centrifuged (1000 rpm,
5 min), resuspended in RNAlater (Qiagen, Hilden, Germany) and stored at −80 ◦C. RNA isolation
was performed using the RNeasy Mini Kit (Qiagen, Hilden, Germany) following the instructions of
the manufacturer. For Mo-DCs gene expression of CD86, CD40, IL-10, MYD88, IRF7 and STAT1 was
assessed. Gene expression levels were normalized against GAPDH and were quantified relative to
time-matched mock stimulated cell cultures. Data were analyzed according to the comparative Ct
method [23] and are expressed as fold change.
2.7. Cytokine Quantification by Multiplex Immunoassay
Cytokine production was determined by Luminex technology. Dendritic cell supernatants were
collected at 24 h after stimulation with the different vaccines. Samples were centrifuged and stored
at −80 ◦C until analysis. The Th1–Th2 cytokine panel containing beads for IL-4, Il-5, IL-6, IL-12p70,
TNF-α and interferon (IFN)-γ was supplemented with the single-plexes for IL-1β, Il-2, IL-8 and IL-10
(all from ProcartaPlex, eBioscience). Briefly, 50 µL of undiluted cell supernatant were added to the
antibody magnetic beads in each of the 96-well plate-wells for 60 min at room temperature. Each
sample was added in duplicate. Next, detection antibodies were added to each well and incubated for
30 min, followed by streptavidin phycoerythrin incubation (50 µL per well). After 30 min of incubation
the beads-sample mixtures were resuspended in Reading Buffer (25 µL) and run on a Luminex
100 analyzer (Luminex Corporation, Austin, TX, USA) following the manufacturer’s instructions.
Calculations were performed using STarStation software (Applied Cytometry Systems, Sheffield, UK).
Data were logarithmically transformed before analysis.
2.8. Statistics
Significant differences between the two vaccines (WIV and SU) were determined using the
unpaired Student’s t test. A p value of p < 0.05 was considered significant.
3. Results
3.1. MUTZ-3 Cells Are Restricted in Their Ability to Respond to Different Stimuli
In order to find a suitable platform for assessing vaccines in vitro we initially turned to MUTZ-3
cells, a cell line similar to primary monocytes in its dependence on cytokines for differentiation to
DCs. We first analyzed the phenotype of the MUTZ-3 cell line prior to differentiation and assessed
whether undifferentiated MUTZ-3 cells could respond to stimuli (Figure 1, panel A). Flow cytometric
analysis showed that undifferentiated MUTZ-3 cells expressed MHCII and CD86 but not CD11c, CD80
or CD40 (Figure 1A, purple lines) indicating that these cells do not have a DC phenotype. As expected,
undifferentiated MUTZ-3 cells did not respond to LPS, known as a strong trigger of DC activation
(Figure 1A, orange lines).
We next tried to differentiate the cells to a dendritic cell phenotype by using various conditions.
Surface marker evaluation indicated that differentiation of MUTZ-3 cells with GM-CSF and IL-4
(Figure 1, panel B) resulted in minor up-regulation of CD11c, a DC phenotype marker (compare purple
lines in Figure 1A,B). Furthermore, there was up-regulation in the expression of CD40 and CD80 and a
more homogenous expression of MHCII but little change in the expression level of CD86. The limited
changes in surface marker expression are in line with microscopical observations indicating that
MUTZ-3 cells differentiated with GM-CSF and IL-4 alone have the same morphological appearance as
undifferentiated cells (data not shown). However, when TNF-α was included in the cytokine mix used
for differentiation (Figure 1, panel C) there was up-regulation of CD11c, demonstrating that under
those conditions the cells differentiated to a DC phenotype (Figure 1C). Up-regulation of CD11c went
along with enhanced expression of MHCII, CD86, CD40 and CD80 as compared to expression on
undifferentiated cells. Morphological observations revealed long dendrites, consistent with a DC-like
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phenotype in differentiated MUTZ-3 cells (data not shown). Thus, successful differentiation was
TNF-α-dependent.
Responsiveness of successfully differentiated MUTZ-3 cells to external stimuli was evaluated by
exposing the cells to LPS. Unexpectedly, surface marker expression of cells stimulated with LPS or
mock-stimulated with PBS did not differ for any of the markers studied (Figure 1C, orange lines).
Unresponsiveness to LPS could be due to a defective function of the LPS itself or to the fact
that the matured status of the DCs was already reached with no possibility of further activation. We
sought to discriminate between these possibilities by using other stimuli. We exposed the cells to a
different batch of LPS, to the TLR7 ligand R848, or to an additional dose of TNF-α. However, 24 h after
stimulation we did not find any difference between the stimulated and mock-stimulated cells in terms
of expression of surface markers for any of the stimuli (Figure 1, panel D). Similarly, neither WIV nor
SU vaccines had any effect on the expression profile of the surface markers.
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From the above results we concluded that differentiated MUTZ-3 cells are refractory to triggering
with toll-like receptor (TLR) ligands or viral vaccines and are thus not suitable for testing responses to
vaccines in vitro.
3.2. Mo-DCs Do Respond to External Stimuli
Since the MUTZ-3 cell line proved unsuitable for the evaluation of responses to external stimuli
and vaccines, we next turned to Mo-DCs. Freshly isolated monocytes from PBMCs of healthy donors
were differentiated to DCs by exposure to GM-CSF and IL-4 for a period of 6 days. Successful
differentiation was confirmed by lack of CD14 expression and expression of the myeloid marker CD11c
(Figure 2). Flow cytometric analysis further revealed that the differentiated DCs had an immature
phenotype characterized by expression of low levels of MHCII and no expression of CD86, CD40, nor
CD80. Stimulation of Mo-DCs with R848 (positive control) already induced MHCII expression at the
4 h time point while the rest of the markers did not show early changes in expression level (Figure 2,
panel A, compare green line (R848) with orange line (PBS control). After 24 h of stimulation with R848,
we found induction of MHCII, CD86, CD80 and to a lesser extent CD40 (Figure 2B). Mo-DCs were
thus able to efficiently respond to a synthetic stimulus.
Next we analyzed the response induced by the two different influenza vaccine formulations.
When Mo-DCs were stimulated with SU vaccine we did not find any significant up-regulation of
any of the markers after 4 h or after 24 h (Figure 2, red line). As a general trend, the SU stimulation
profile always mimicked the profile of the mock-stimulated cells. In contrast, WIV already elicited
up-regulation of MHCII at the 4 h time point. After 24 h of stimulation with WIV, there was a significant
up-regulation of MHCII, CD86, CD80 and CD40, consistent with an activated DC phenotype (Figure 2B,
green line). This phenotype was similar to that of cells stimulated with R848. Differential expression of
surface markers elicited by WIV and SU was consistently found for Mo-DCs derived from four different
donors with only minor variation, reflected in the relatively small standard deviations (Figure 2C).
Thus, Mo-DCs responded in characteristic ways to SU and WIV and the responses were in line with
the magnitude of the immune responses these vaccine evoke in vivo.
To further evaluate the ability of Mo-DCs to respond to stimuli and to different vaccines in a
characteristic way, we assessed the expression of selected genes involved in the immune response
by reverse transcription polymerase chain reaction (RT-qPCR). For this, we chose genes coding for
the adaptor protein MYD88, a transcription factor involved in the TLR signaling pathway (IRF7),
a transcription factor involved in the response to interferons (STAT1) and genes coding for surface
markers relevant for the DC phenotype (CD40 and CD80) (Figure 3). Our results reveal that 4 h
stimulation with R848 induced up-regulation in the gene expression levels of CD40 and to a lower
extent IRF7, while the other investigated genes showed less than 2-fold changes in expression. After
24 h of stimulation, the expression levels of most genes were back to the levels in control cells. SU
vaccine did not successfully stimulate the Mo-DCs. This was reflected by the absence of an evident up-
or down-regulation of any of the genes at 4 h and 24 h. WIV-stimulated cells showed more than 2-fold
upregulation compared to the mock-stimulated controls in all of the investigated genes. The difference
in fold change of gene expression between WIV- and SU-stimulated cells was significant for most of
the genes except for CD86 at the 4 h time point and MYD88 at the 24 h time point. The fold increase
in induction elicited by WIV was higher than the one elicited by the synthetic TLR7 ligand R848.
While the expression of most markers had returned to normal levels after 24 h of R848 stimulation
the increase in marker expression was sustained in cells stimulated with WIV. All four investigated
donors responded in the same way and to a similar extent to stimulation with R848, SU and WIV as
reflected in the relative small standard deviations shown in Figure 3.
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Figure 6. Differences in gene expression induced by WIV and SU are consistent in Mo-DCs derived 
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PBMCs from matching donors. Cells were stimulated for 4 h (A) and 24 h (B). Results are expressed 
as mean log2 fold change compared to mock-stimulated cells (n = 4); (C) Quantitative representation 
of the gene expression data. Bars represent the mean log2 fold change in gene expression as compared 
to the medium control of four different donors +/− standard deviation. 
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potential tool to investigate features of DC biology and immunology. However, while some groups 
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4. iscussion
In order to develop an in vitro system for pre-screening of vaccine candidates, we have set out to
identify a suitable human cellular platform to assess responses towards vaccines using WIV and SU
influenza vaccines as model antigens. We demonstrate that the MUTZ-3 cell line does not show any
reaction to the vaccines and is thus unsuitable as a platform for an in vitro vaccine screening system.
In contrast, human primary Mo-DCs did respond to exposure to the vaccines. More importantly, as
previously described for mouse bone marrow-derived cells, Mo-DCs responded in a vaccine-specific
manner and the response was in agreement with the kno n in vivo immunogenicity of the two
vaccines [22,24,25]. The ability to respond distinctly towards different vaccine formulations was not
hampered when Mo-DCs were derived from frozen PBMCs. Overall, the response obtained across DCs
from a number of different donors was consistent. To our knowledge, we are the first to systematically
compare responses to stimuli in cells derived from fresh and frozen cells and to carefully assess
variation in responses in cells derived from different donors across different read-outs. Our results
support the feasibility of using an in vitro approach using human PBMC-derived DCs to estimate
in vivo responses elicited by different vaccine formulations.
Recently, the UTZ-3 cell line has been proposed as a suitable DC in vitro model [14,26,27]
and potential tool to investigate features of DC biology and immunology. However, while some
groups have claimed this cell line mimics primary DCs in different aspects such as phenotype,
transcriptional profile and their capacity to induce T cell proliferation [14,27–31]; others have reported
impaired responsiveness to certain stimuli and transcriptional and functional defects in this cell
line [5,9,32,33]. Regardless, when compared to other DC-like cell lines (THP-1, Monomac6, HL-60,
U937), MUTZ-3 most closely mimics DCs [27–29,31,34]. To differentiate into DC-like cells, MUTZ-3
appears to require TNF-α (our own observations and those of others [14,30,32,33]). Overall, there is a
lot of discrepancy on the differentiation conditions of this cell line, especially on its dependency on
TNF-α for differentiation. We and others [5] found the culture conditions of this particular cell line
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a challenging issue. Differentiated MUTZ-3 cells (expressing CD11c) did not show an immature DC
status in any of our experiments or conditions. They rather displayed already a mature phenotype that
could not be further stimulated. Contrary to Mo-DCs, differentiated MUTZ-3 cells could not effectively
respond to the stimuli and we did not find differences between PBS-treated cells (our negative control)
and cells stimulated with LPS or R848 in terms of surface marker expression. While this is in
accordance with previous studies [9,33] that support the observed unresponsiveness of MUTZ-3,
others have shown responses from this particular cell line upon stimulation with different components
of Haemophilus influenzae [30]. Non-reactivity of MUTZ-3 cells to LPS stimulation has been linked to
an impairment of the intracellular domain of the receptor (TLR4) or its interaction with the adaptor
protein (MyD88) [33]. Additionally, MUTZ-3 cells have been shown to be selectively defective in their
responses to pathogen-associated molecular patterns (PAMPs), but not to other types of stimulation
(i.e., cytokines) which use different receptors and other intracellular signaling pathways [9]. These
functional defects have been associated with the down-regulation of different gene clusters like those
involved in pathogen recognition, DC maturation and cytokine/chemokine signaling in response to
microbial stimulation [9]. We believe that dysregulation of these genes involved in TLR signaling
pathways may explain why MUTZ-3 failed to respond to different ligands (LPS or R848) and to
vaccines in our hands. The use of different readouts and stimuli different from ours (e.g., functional
assays for antigen presentation and T cell stimulation) can explain why this cell line has proven useful
to assess to a certain extent the biological and functional aspects of DCs [5,27–29,31]. Notwithstanding,
for our particular purpose, MUTZ-3 proved not to be a suitable model for studying responses towards
different vaccine formulations.
The restricted ability of MUTZ-3 to respond to different stimuli prompted us to assess in
a systematic way as to what degree DCs derived from PBMCs would be suitable as an in vitro
vaccine screening platform. So far, human DCs have been mainly used to study vector [35–38],
adjuvanted [30,35,39] or live attenuated vaccines [40,41] thus mainly focusing on the mechanism
of action of the vector/adjuvant rather than on the vaccine itself. In contrast, we used next to TLR
ligands two commercially available, inactivated and non-adjuvanted human vaccines known to differ
in the responses they elicit in vivo [24,25]. Firstly, we demonstrate that in contrast to MUTZ-3 cells,
Mo-DCs do respond to these vaccines; Secondly, we show that Mo-DCs respond to the vaccines in
specific ways. The WIV vaccine activated Mo-DCs more effectively than the SU formulation. WIV
efficiently elicited DC maturation, increasing the expression levels of surface and activation markers.
The magnitude of the response was similar to and in some cases even higher than the magnitude of
the response obtained by synthetic molecules like the TLR7 ligand, R848. Moreover, by using three
different read-outs we found that WIV was capable of inducing upregulation of surface markers, and
increased expression of genes relevant for the immune response and production of cytokines. The
observed up-regulation of genes related to TLR signaling (MYD88, IRF7) further supports the notion
that WIV stimulates Mo-DC by TLR7-triggering. The superiority of WIV over SU in activation of DCs
has been previously shown by our lab for cultured DCs from mice [22]. Due to its composition, the
WIV vaccine is intrinsically adjuvanted with viral ssRNA; this enables triggering of pattern recognition
receptors (PRRs) like TLR7 and the subsequent activation of DCs [13]. Conversely, SU-treated cells
did not display a surface marker phenotype consistent with mature/activated DCs, nor did they show
any response in terms of gene expression. The SU vaccine is composed of proteins (HA and NA) that
cannot be recognized by PRRs. This is consistent with the poor stimulation and low expression levels of
surface markers observed by us.
Generally, the use of PBMCs or PBMC-derived cells is associated with the problem of donor
variability and the fact that responses may be inconsistent across different readouts [11,42,43]. Recently,
Li and colleagues [11] addressed the donor variability of immune responses to bacterial and fungal
pathogens by assessing cytokine production. Regulation of the pathogen-specific responses was only
partially genetically influenced, suggesting that external factors are also involved in the modulation of
cytokine responses. In line with this, stimulation of MoDCs with WIV or SU did not show consistent
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effects on cytokine expression. From our results, we can conclude that not all readouts are suitable to
pre-screen vaccine immunogenicity in this particular in vitro DC system. By combining the expression
of surface/activation markers and specific genes as our main readouts we found consistent responses
to the different vaccines across readouts and amongst the different donors. Additional extensive gene
expression analysis could help to elucidate the mechanism of action of different vaccines. As for
the production of cytokines, consistent vaccine-specific changes in expression were induced in the
Mo-DCs, despite the inherent donor-to donor variation [11]. Nevertheless, the presence of low and
high responders, which differ largely in the amount of cytokines they secrete, renders cytokine profiling
a less suitable readout for the Mo-DC system.
Another disadvantage of using primary Mo-DCs for vaccine assessment is the limited and
time-restricted availability of PBMCs. However, when comparing Mo-DCs from fresh and frozen
PBMCs, we observed that the capability of the cells to respond to different stimuli was not affected
by the freeze/thaw process. This observation underlines that frozen PBMCs can be used for the
generation of DCs, which largely enhances flexibility and reproducibility. Altogether, both the here
reported consistency amongst donors and the possibility of using cryopreserved PBMCs highlight the
feasibility of a primary DC-based in vitro system for the evaluation of vaccine candidates.
Our data demonstrates that Mo-DCs are capable of responding to vaccines in measurable and
consistent ways even if the vaccines are inactivated and non-adjuvanted. However, not all vaccines
are capable of activating DCs. A good example of an adjuvant that does not induce DC responses is
the oil-in-water compound AS03 that was approved for use in an integral part of pandemic influenza
vaccines [44]. In view of this restriction there is a clear need to include additional types of immune
cells to develop a cell-based in vitro system that allows a more extended assessment of vaccine
immunogenicity and a detailed study of a vaccine’s mode of action.
In summary, during the differentiation to a DC-like phenotype, the MUTZ-3 cell line was already
too activated and no further up-regulation of markers could be induced by any of the used stimuli.
This characteristic renders the MUTZ-3 cell line an unsuitable model to mimic DCs. On the other
hand, primary Mo-DCs, irrespective whether they were derived from fresh or frozen PBMCs, showed
low variation amongst donors and proved to be a robust and reproducible platform to assess vaccine
immunogenicity. We conclude that human Mo-DCs derived from frozen PBMCs are a flexible and
robust platform for the evaluation of the immunogenicity of vaccine candidates and for the assessment
of vaccine-induced immune mechanisms.
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